NCT03053791 Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait
| NCT ID | NCT03053791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Spinal Cord Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2018-03-15 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5 participants in total. It began in 2018-03-15 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. One of the most plastic systems involved in locomotion is the pontomedullary reticulospinal tract, which is the oldest locomotor command system existing in most vertebrates, including primates. Muscle activation patterns for limb movements are programmed in the spinal cord and have to be activated and coordinated through commands from the so called mesencephalic locomotor region (MLR). The MLR consists of nerve cells in the lower mesencephalic tegmentum sending uni- and bilateral signals through the medullary reticulospinal tracts. Classical physiological studies showed that electrical stimulation of the MLR induce locomotion. For the first time this approach was transferred and recently published in a model of induced incomplete spinal cord injury by the Schwab group. Rats severly impaired in motor hindlimb control with only 10-20% spared white matter, recovered with fully functional weight bearing locomotion under MLR deep brain stimulation (DBS). Even rats with only 2-10% spared white matter regained weight supporting stepping. DBS is a clinical standard treatment option in patients with movement disorders but does not relieve all symptoms. Therefore, small studies of MLR stimulations have been safely used in Parkinsonian patients showing freezing of gait and frequent falls with variable results. In a translational approach, we aim at performing a multidisciplinary phase one clinical trial with 5 patients and incomplete spinal cord injury. With the means of our established universitary setup for DBS treatments the operations will be performed unilaterally under local anaesthesia in the Division of Neurosurgery, USZ, with perioperative electrophysiological recordings, clinical assessments and gait analysis under test stimulation in the Spinal Cord Injury Center Balgrist.
Eligibility Criteria
Inclusion Criteria: 1. Informed Consent 2. Participation in two assessment sessions before enrollment (Screening and baseline) 3. Willingness and ability to comply with the protocol and to attend required study training and visits 4. Male or female subjects 5. Age 18-75 6. Motor incomplete SCI 7. Level of lesion: T10 and above, based on AIS level, preservation of sacral function 8. Focal spinal cord disorder caused by either trauma or non-traumatic and non-progressive condition (like hemorrhage, benign tumor) 9. Minimum 3 months of recovery after SCI 10. Completed in-patient rehabilitation program 11. WISCI II, level \>2 (0-20 items): assistance of one or more persons. Ability to walk at least 10 meters 12. Stable medical and physical condition. 13. Adequate care-giver support and access to appropriate medical care in patient's home community Exclusion Criteria: 1. Enrollment of the investigator, his/her family members, employees and other dependent persons 2. Limitation of standing and walking function based on accompanying (CNS) disorders 3. Cardiovascular disorders restricting physical training or peripheral nerve disorders 4. Implanted technical devices (pacemaker, defibrillator) 5. History of significant autonomic dysreflexia 6. Cognitive disorders/brain damage 7. Drug refractory epilepsy 8. Severe joint contractures disabling or restricting lower limb movements 9. Haematological disorders with increased risk of bleeding during surgical interventions 10. Participation in another study with investigational drug within the 30 days preceding and during the present study 11. Congenital or acquired lower limb abnormalities (affection of joints and bone) 12. Women who are pregnant or breast feeding or planning a pregnancy during the course of the study 13. Lack of safe contraception 14. Inability of the participant to follow the procedures of the study, e.g. due to language problems, psychological problems, dementia etc. 15. Known or suspected non-compliance, drug or alcohol abuse 16. Current or prior malignancy
Contact & Investigator
Lennart H Stieglitz, MD
PRINCIPAL INVESTIGATOR
University Hospital Zurich, Neurosurgery
Frequently Asked Questions
Who can join the NCT03053791 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03053791 currently recruiting?
Yes, NCT03053791 is actively recruiting participants. Contact the research team at Lennart.Stieglitz@usz.ch for enrollment information.
Where is the NCT03053791 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT03053791 clinical trial?
NCT03053791 is sponsored by University of Zurich. The principal investigator is Lennart H Stieglitz, MD at University Hospital Zurich, Neurosurgery. The trial plans to enroll 5 participants.